A sub-study in 37 patients in the pivotal trial CLEOPATRA showed no evidence of drug-drug interaction between Pertuzumab and trastuzumab and between Pertuzumab and docetaxel. In addition no clinically relevant pharmacokinetic interaction of co-administered docetaxel or trastuzumab on Pertuzumab was evident based on the population pharmacokinetics analysis. This lack of drug-drug interaction was confirmed by pharmacokinetic data from the NEOSPHERE and APHINITY studies.
Five studies evaluated the effects of Pertuzumab on the pharmacokinetics of co-administered cytotoxic agents, docetaxel, paclitaxel, gemcitabine, capecitabine, Carboplatin, and erlotinib. There was no evidence of any pharmacokinetics interaction between Pertuzumab and any of these agents. The pharmacokinetics of Pertuzumab in these studies was comparable to those observed in single-agent studies.